Anne Fourie, MSc, PhD

Janssen Research & Development, LLC

Poster(s):

• P2167 - Characterization of a First-in-Class Oral Therapy Selectively Targeting the IL-23 Pathway
  Monday, October 23, 2023

  10:30 AM – 4:15 PM PT